Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sayoko Iizuka"'
Autor:
Miho Wada, Yohta Shimada, Sayoko Iizuka, Natsumi Ishii, Hiromi Hiraki, Toshiaki Tachibana, Kazuhiro Maeda, Mitsuru Saito, Shoutaro Arakawa, Takuya Ishimoto, Takayoshi Nakano, Hiroyuki Ida, Toya Ohashi, Hiroshi Kobayashi
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 261-274 (2020)
Mucopolysaccharidosis type II is a disease caused by organ accumulation of glycosaminoglycans due to iduronate 2-sulfatase deficiency. This study investigated the pathophysiology of the bone complications associated with mucopolysaccharidosis II and
Externí odkaz:
https://doaj.org/article/d2d11fb78c1542e5850cea2f318246be
Autor:
Masahisa Kobayashi, Toya Ohashi, Sayoko Iizuka, Eiko Kaneshiro, Takashi Higuchi, Yoshikatsu Eto, Hiroyuki Ida
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 1, Iss C, Pp 283-287 (2014)
We examined alpha-galactosidase A (GLA) gene mutations in 74 Japanese families with Fabry disease (FD) to determine the frequency of de novo mutations. In 5 of 74 families (6.8%), the probands had no positive family histories and were diagnosed as de
Externí odkaz:
https://doaj.org/article/e26b6b49fe23409bbbe9314dbc294bd5
Autor:
Sayoko Iizuka, Yohei Sato, Kazuhito Fujiyama, Takao Ohashi, Juthamard Limkul, Ryo Misaki, Toya Ohashi
Publikováno v:
Plant Biotechnology Journal
Summary For the production of therapeutic proteins in plants, the presence of β1,2‐xylose and core α1,3‐fucose on plants’ N‐glycan structures has been debated for their antigenic activity. In this study, RNA interference (RNAi) technology w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7153f997e2eb1521d7d442832b5ebcfb
https://doi.org/10.1111/pbi.12529
https://doi.org/10.1111/pbi.12529
Autor:
Toya Ohashi, Yoshikatsu Eto, Eiko Kaneshiro, Takashi Higuchi, Hiroyuki Ida, Sayoko Iizuka, Masahisa Kobayashi
Publikováno v:
Molecular Genetics and Metabolism Reports
Molecular Genetics and Metabolism Reports, Vol 1, Iss C, Pp 283-287 (2014)
Molecular Genetics and Metabolism Reports, Vol 1, Iss C, Pp 283-287 (2014)
We examined alpha-galactosidase A (GLA) gene mutations in 74 Japanese families with Fabry disease (FD) to determine the frequency of de novo mutations. In 5 of 74 families (6.8%), the probands had no positive family histories and were diagnosed as de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feea32a44e1995606d58f13574916928
http://europepmc.org/articles/PMC5121308
http://europepmc.org/articles/PMC5121308
Autor:
Sayoko Iizuka, Takashi Higuchi, Hiroshi Kobayashi, Toya Ohashi, Yoshikatsu Eto, Hiroyuki Ida, Yohta Shimada
Publikováno v:
Molecular Therapy. 20(10):1924-1931
Animal and human studies of enzyme replacement therapy (ERT) for Pompe disease (PD) have indicated that antibodies (Abs) generated against infused recombinant human α-glucosidase (rhGAA) can have a negative impact on the therapeutic outcome and caus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa214d6cfc112ab7cfcb2dd13e84247
Autor:
Takahiro Kimura, Toya Ohashi, S O Kyosen, Jin-Song Shen, Hiroyuki Ida, Yohta Shimada, Sayoko Iizuka, Yoshikatsu Eto, Takahiro Fukuda, Hiroshi Kobayashi
Publikováno v:
Gene Therapy. 17:521-530
Pompe disease results from the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to accumulated glycogen in the heart and the skeletal muscles, which causes cardiomyopathy and muscle weakness. In this study, we tested the feasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c17ef122b4006e431a6bd8ba4738ce7
https://doi.org/10.1038/gt.2009.160
https://doi.org/10.1038/gt.2009.160
Publikováno v:
European Journal of Haematology. 61:235-239
We succeeded in efficiently transferring the beta-glucuronidase gene in a retroviral vector to human hematopoietic progenitor cells using a centrifugation enhancement protocol. The transduction efficiency in CFU-GM was highly variable (23-100%) with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::435bc3f1d766e68f61d14f33039de8c7
https://doi.org/10.1111/j.1600-0609.1998.tb01708.x
https://doi.org/10.1111/j.1600-0609.1998.tb01708.x
Publikováno v:
Molecular Genetics and Metabolism. 94:313-318
Fabry disease is a progressive, life-threatening lysosomal storage disorder which is characterized by deficient activity of the lysosomal enzyme alpha-galactosidase A. Studies have demonstrated that both enzyme preparations currently available for tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdb35722279cec24d3f388e971152970
https://doi.org/10.1016/j.ymgme.2008.03.008
https://doi.org/10.1016/j.ymgme.2008.03.008
Autor:
Sayoko Iizuka, Jin-Song Shen, Xing-Li Meng, Akihiro Umezawa, Taisuke Mori, Ken Sakurai, Toya Ohashi, Yoshikatsu Eto
Publikováno v:
Gene Therapy. 11:1475-1481
Current therapies for lysosomal storage diseases (LSDs), enzyme replacement therapy and bone marrow transplantation are effective for visceral organ pathology of LSD, but their effectiveness for brain involvement in LSDs is still a subject of controv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe2a9dfdeffd68cfd350bd23f0fb2251
https://doi.org/10.1038/sj.gt.3302338
https://doi.org/10.1038/sj.gt.3302338
Autor:
Yohta Shimada, Sayoko Iizuka, T. Ohashi, Satoshi Hachimura, Hiroshi Kobayashi, Hiroyuki Ida, Yoshikatsu Eto
Publikováno v:
Molecular Genetics and Metabolism. 103:98-100
Animal and human studies of enzyme replacement therapy for Pompe disease have indicated that antibodies generated against the infused recombinant human acid α-glucosidase (rhGAA) can negatively impact therapeutic outcome. In this study, we show that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae7b33d87b0529f870090a7ce973a6b
https://doi.org/10.1016/j.ymgme.2011.01.009
https://doi.org/10.1016/j.ymgme.2011.01.009